[go: up one dir, main page]

PE20051151A1 - Profarmacos de piperazina y agentes antivirales de piperidina - Google Patents

Profarmacos de piperazina y agentes antivirales de piperidina

Info

Publication number
PE20051151A1
PE20051151A1 PE2005000289A PE2005000289A PE20051151A1 PE 20051151 A1 PE20051151 A1 PE 20051151A1 PE 2005000289 A PE2005000289 A PE 2005000289A PE 2005000289 A PE2005000289 A PE 2005000289A PE 20051151 A1 PE20051151 A1 PE 20051151A1
Authority
PE
Peru
Prior art keywords
methyl
piperazine
pro
drugs
compounds
Prior art date
Application number
PE2005000289A
Other languages
English (en)
Inventor
Yasutsugu Ueda
Timothy P Connolly
John F Kadow
Tao Wang
Kap-Sun Yeung
David Kenneth Leahy
Nachimuthu Soundararajan
Kathia Levesque
Dominique Thoraval
Pierre Sirard
Shawn K Pack
Zhongxing Zhang
Chung-Pin H Chen
Nicholas A Meanwell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20051151(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20051151A1 publication Critical patent/PE20051151A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A COMPUESTOS DE PROFARMACO DE FORMULA I DONDE X ES C, N; W ES C, N; V ES C; R1 H, METOXI, HALOGENO; R2 ES H; R3 ES METOXI, HETEROARILO; E ES H, SAL TIPO MONO O BIS; Y ES (a), (b); R10, R11, R13, R14, R15, R16 Y R17 SON CADA UNO H, METILO; R18 C(O)-FENILO, C(O)-PIRIDINILO, QUINAZOLILO, ENTRE OTROS; D ES CIANO, HALOGENO, FENILO, ENTRE OTROS; A ES FENILO, FURILO, TIENILO, ENTRE OTROS. TAMBIEN REFERIDA A UN PROCEDIMIENTO PARA LA PREPARACION DE ESTOS COMPUESTOS Y DE SUS INTERMEDIARIOS CUYOS PREFERIDOS SON: FOSFATO DIACIDO DE {3-[(4-BENZOPIPERAZIN-1-IL)(OXO)ACETIL]-4,7-DIMETOXI-1H-PIRROLO[2,3-c]PIRIDIN-1-IL}METILO; FOSFATO DIACIDO DE [3-[(4-BENZOPIPERAZIN-1-IL)(OXO)ACETIL]-4-FLUORO-7-(1H-1,2,3-TRIAZOL-1-IL)-1H-PIRROLO(2,3-c]PIRIDIN-1-IL]METILO; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE INFECCIONES POR VIH
PE2005000289A 2004-03-15 2005-03-15 Profarmacos de piperazina y agentes antivirales de piperidina PE20051151A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55332004P 2004-03-15 2004-03-15
US63523104P 2004-12-10 2004-12-10

Publications (1)

Publication Number Publication Date
PE20051151A1 true PE20051151A1 (es) 2006-01-20

Family

ID=34963934

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000289A PE20051151A1 (es) 2004-03-15 2005-03-15 Profarmacos de piperazina y agentes antivirales de piperidina

Country Status (26)

Country Link
US (12) US7745625B2 (es)
EP (1) EP1725569B1 (es)
JP (1) JP4734318B2 (es)
KR (1) KR101153594B1 (es)
CN (1) CN101941990B (es)
AR (1) AR048039A1 (es)
AT (1) ATE384728T1 (es)
AU (1) AU2005223736C1 (es)
BR (1) BRPI0508876B8 (es)
CA (1) CA2560253C (es)
CY (1) CY1107419T1 (es)
DE (1) DE602005004517T2 (es)
DK (1) DK1725569T3 (es)
ES (1) ES2299022T3 (es)
GE (1) GEP20094736B (es)
HR (1) HRP20080064T5 (es)
IL (1) IL211961A (es)
MY (1) MY139243A (es)
NO (1) NO336742B1 (es)
NZ (2) NZ585294A (es)
PE (1) PE20051151A1 (es)
PL (1) PL1725569T3 (es)
PT (1) PT1725569E (es)
RS (1) RS50567B (es)
TW (1) TWI344843B (es)
WO (1) WO2005090367A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
RS51752B (sr) * 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
US20050075364A1 (en) 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
RS53109B (sr) * 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7130185B2 (en) * 2004-06-02 2006-10-31 Research In Motion Limited Handheld computing device having drop-resistant LCD display
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
KR101278397B1 (ko) * 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. 2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7396830B2 (en) 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7504399B2 (en) * 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
EP2303876B1 (en) * 2008-06-25 2014-03-19 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
ES2389478T3 (es) * 2008-06-25 2012-10-26 Bristol-Myers Squibb Company Derivados de dicetopiperidina como inhibidores de la fijación del VIH
CA2735008C (en) * 2008-09-04 2016-11-29 Bristol-Myers Squibb Company Extended release formulation for optimized delivery of an hiv attachment inhibitor
EP2349973A2 (en) * 2008-10-20 2011-08-03 XenoPort, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US8686009B2 (en) * 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
RU2537137C2 (ru) * 2009-11-09 2014-12-27 Ксенопорт, Инк. Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения
MX2012013703A (es) 2010-06-04 2012-12-17 Bristol Myers Squibb Co Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
DK2576586T3 (en) 2010-06-04 2015-11-23 Bristol Myers Squibb Co C-28 AMINES OF MODIFIED C-3-BETULIN ACID DERIVATIVES AS ANTI-HUMIDITY INHIBITORS
WO2012019003A1 (en) 2010-08-06 2012-02-09 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
DK2670764T3 (en) 2011-01-31 2015-12-07 Bristol Myers Squibb Co C-28 AMINES OF MODIFIED C-3-BETULIN ACID DERIVATIVES AS ANTI-HUMIDITY INHIBITORS
SG191841A1 (en) * 2011-01-31 2013-08-30 Bristol Myers Squibb Co Methods of making hiv attachment inhibitor prodrug compound and intermediates
EA022470B1 (ru) 2011-01-31 2016-01-29 Бристол-Маерс Сквибб Компани C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EP2696937B1 (en) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
WO2013033059A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
WO2013033061A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as hiv attachment inhibitors
CA2849475A1 (en) 2011-09-21 2013-03-28 Bristol-Myers Squibb Company Novel betulinic acid derivatives with antiviral activity
EP2783219A1 (en) 2011-11-21 2014-10-01 Bristol-Myers Squibb Company Methods for determining the susceptibility of a virus to an attachment inhibitor
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
EP2812332B1 (en) * 2012-02-08 2017-08-09 Viiv Healthcare Uk (No. 4) Limited Methods for the preparation of hiv attachment inhibitor piperazine prodrug compound
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
RS58898B1 (sr) 2012-06-19 2019-08-30 Debiopharm Int Sa Prolek derivati (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamida
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
US9505752B2 (en) 2012-08-09 2016-11-29 Viiv Healthcare Uk (No. 5) Limited Piperidine amide derivatives as HIV attachment inhibitors
CA2900124A1 (en) 2013-02-06 2014-08-14 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
EP2958930A1 (en) 2013-02-25 2015-12-30 Bristol-Myers Squibb Company C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
WO2014160689A1 (en) * 2013-03-27 2014-10-02 Bristol-Myers Squibb Company Piperazine and homopiperazine derivatives as hiv attachment inhibitors
CN105283455B (zh) * 2013-03-27 2017-06-16 百时美施贵宝公司 作为hiv吸附抑制剂的2‑酮基酰胺衍生物
HRP20201645T1 (hr) 2014-04-11 2020-12-25 VIIV Healthcare UK(No.4) Limited Triterpenoidi s aktivnošću inhibiranja zrenja hiv, supstituirani na položaju 3 nearomatskim prstenom koji nosi halogenalkilni supstituent
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
WO2016077561A1 (en) 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Oxolupene derivatives
US10047118B2 (en) 2014-11-14 2018-08-14 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
CA2971104A1 (en) 2014-12-18 2016-06-23 ViiV Healthcare UK (No.4) Limited A process for preparing halogenated azaindole compounds using boroxine
CN107428748A (zh) 2014-12-18 2017-12-01 Viiv保健英国第四有限公司 使用pybrop制备卤化氮杂吲哚化合物的方法
US20180094019A1 (en) 2015-04-14 2018-04-05 ViiV Healthcare UK (No.4) Limited Crystalline forms of modified triterpenoid hydrochloride salts with hiv maturation inhibitor activity
IL310489A (en) 2015-10-01 2024-03-01 Olema Pharmaceuticals Inc TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS AND COMPOSITIONS COMPRISING SAME FOR USE IN TREATING CANCER
KR102671166B1 (ko) * 2015-12-14 2024-05-31 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 3,5-디페닐-디아졸 화합물의 수용성 유도체
JP2019508399A (ja) 2016-02-04 2019-03-28 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド 多くの治療を経験したｈｉｖ−１に感染した個体において使用するためのホステムサビル
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
PT3419628T (pt) 2016-02-26 2021-01-05 Debiopharm Int Sa Medicamento para o tratamento de infeções do pé diabético
IL274820B2 (en) 2017-11-21 2024-11-01 Pfizer Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid
ES2972293T3 (es) 2019-01-17 2024-06-12 Viiv Healthcare Uk No 4 Ltd Procedimiento para preparar fostemsavir
CA3129508A1 (en) 2019-02-14 2020-08-20 Debiopharm International S.A. Solid formulations of afabicin with histidine
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途
KR20220034129A (ko) 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
CN118475353A (zh) 2021-12-17 2024-08-09 Viiv保健公司 用于hiv感染的联合疗法及其用途
EP4611813A1 (en) 2022-11-02 2025-09-10 VIIV Healthcare UK (No.5) Limited Antigen binding proteins
WO2025229019A1 (en) 2024-04-30 2025-11-06 VIIV Healthcare UK (No.5) Limited Neutralizing antibody constructs against hiv
WO2025229018A1 (en) 2024-04-30 2025-11-06 VIIV Healthcare UK (No.5) Limited Neutralizing antibody constructs against hiv

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2101017C (en) 1992-07-24 1999-10-26 Masahiko Higuma Ink jet cartridge, ink jet head and printer
US6469006B1 (en) 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
ES2250422T3 (es) * 2000-07-10 2006-04-16 Bristol-Myers Squibb Company Composicion y actividad antiviral de derivados de piperazina indoloxoaceticos sustituidos.
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
KR20030079979A (ko) * 2001-02-02 2003-10-10 브리스톨-마이어스스퀴브컴파니 치환된 아자인돌옥소아세틱 피페라진 유도체의 조성물 및항바이러스 활성
AU2003215469A1 (en) 2002-03-28 2003-10-13 Procyon Biopharma Inc. Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7776863B2 (en) 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US7130185B2 (en) * 2004-06-02 2006-10-31 Research In Motion Limited Handheld computing device having drop-resistant LCD display
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
SG191841A1 (en) * 2011-01-31 2013-08-30 Bristol Myers Squibb Co Methods of making hiv attachment inhibitor prodrug compound and intermediates
EP2812332B1 (en) * 2012-02-08 2017-08-09 Viiv Healthcare Uk (No. 4) Limited Methods for the preparation of hiv attachment inhibitor piperazine prodrug compound

Also Published As

Publication number Publication date
US20190111066A1 (en) 2019-04-18
BRPI0508876B8 (pt) 2021-05-25
MY139243A (en) 2009-09-30
PL1725569T3 (pl) 2008-09-30
RU2374256C2 (ru) 2009-11-27
DK1725569T3 (da) 2008-06-02
US20050209246A1 (en) 2005-09-22
WO2005090367A1 (en) 2005-09-29
AR048039A1 (es) 2006-03-22
US20210023098A1 (en) 2021-01-28
NZ585294A (en) 2011-09-30
NZ549867A (en) 2010-07-30
US20180000849A1 (en) 2018-01-04
AU2005223736C1 (en) 2011-10-06
GEP20094736B (en) 2009-07-27
HK1096687A1 (en) 2007-06-08
US8168615B2 (en) 2012-05-01
CY1107419T1 (el) 2012-12-19
TWI344843B (en) 2011-07-11
HK1148533A1 (en) 2011-09-09
US20120238755A1 (en) 2012-09-20
US20160361328A1 (en) 2016-12-15
CA2560253C (en) 2013-01-15
ATE384728T1 (de) 2008-02-15
CN101941990A (zh) 2011-01-12
CA2560253A1 (en) 2005-09-29
KR20060129533A (ko) 2006-12-15
NO336742B1 (no) 2015-10-26
HRP20080064T3 (hr) 2008-03-31
ES2299022T3 (es) 2008-05-16
US8871771B2 (en) 2014-10-28
DE602005004517D1 (de) 2008-03-13
US20200046743A1 (en) 2020-02-13
US20150232414A1 (en) 2015-08-20
JP2007529519A (ja) 2007-10-25
CN101941990B (zh) 2012-04-25
NO20064062L (no) 2006-12-08
US8461333B2 (en) 2013-06-11
US20150025240A1 (en) 2015-01-22
EP1725569A1 (en) 2006-11-29
US7745625B2 (en) 2010-06-29
RS50567B (sr) 2010-05-07
DE602005004517T2 (de) 2009-01-22
BRPI0508876B1 (pt) 2020-05-26
RU2006136390A (ru) 2008-04-27
AU2005223736B2 (en) 2011-05-26
US20130253196A1 (en) 2013-09-26
JP4734318B2 (ja) 2011-07-27
US11369624B2 (en) 2022-06-28
KR101153594B1 (ko) 2012-07-05
US20100210599A1 (en) 2010-08-19
HRP20080064T5 (en) 2008-10-31
TW200600096A (en) 2006-01-01
IL211961A (en) 2013-08-29
BRPI0508876A (pt) 2007-09-04
PT1725569E (pt) 2008-03-28
US20150315218A1 (en) 2015-11-05
AU2005223736A1 (en) 2005-09-29
EP1725569B1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
PE20051151A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina
HUP0300693A2 (hu) Eljárás epotilon-analógok és -intermedierek előállítására
PE20020104A1 (es) Derivados de benzotiazol
PE20030713A1 (es) Derivados benzotiazol de nicotina o isonicotina
CO5540302A2 (es) Heteroarilos multiciclicos con quinuclidinas para el tratamiento de enfermedades
MEP12708A (en) Derivatives of n-[phenyl (alkylpiperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
PE20050354A1 (es) Aminas ciclicas de bace-1 que poseen un sustituyente heterociclico
MY147730A (en) Metabotropic glutamate receptor antagonists
ATE179711T1 (de) 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine
DE59510162D1 (de) Nucleosid-derivate mit photolabilen schutzgruppen
DK0586471T3 (da) Perhydroisoindolderivater og deres fremstilling
PE20060837A1 (es) COMPUESTOS DE 3H-OXAZOLO Y 3H-TIAZOLO[4,5-d]PIRIMIDIN-2-ONA 3,5-DISUSTITUIDA Y 3,5,7-TRISUSTITUIDA Y PROFARMACOS DE LOS MISMOS
ATE368049T1 (de) Nukleotidderivate mit einer reportergruppe und einer polymerase-enzym-blockierende gruppe
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
MXPA04000532A (es) Derivados de 8-metoxi-(1,2,4)-triazolo(1,5-a)piridina y su uso como ligandos receptores de adenosina.
DE69823648D1 (de) 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4)
SE0301446D0 (sv) New Compounds
DK1109817T3 (da) Phosphohalogenhydriner, deres fremstilling og anvendelse
RO90599B (ro) Compozitie fungicida solida, pe baza de compusi cu fosfor
PE20050587A1 (es) Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales
AR029268A1 (es) Agentes herbicidas
ATE296300T1 (de) Benzoheterocyclische distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
SI1644389T1 (sl) Pirimidinske spojine s fosfonatnimi skupinami kot antivirusni nukleotidni analogi
PE14896A1 (es) Aminoalcanimidazoles y triazoles acilados
ATE133938T1 (de) Indan-1,3-dion und indan-1,2,3-trionderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung

Legal Events

Date Code Title Description
FG Grant, registration